Accustem Sciences Inc. (ACUT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD.

Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-1.8M -1.2M -600K 0 600K 1.2M 1.8M 2024: -1.5M 2025: -1.8M 2024 2025

Net Income Annual

-1.8M -1.2M -600K 0 600K 1.2M 1.8M 2024: -1.5M 2025: -1.8M 2024 2025

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-900K -600K -300K 0 300K 600K 900K 2024: -664.1K 2025: -850.4K 2024 2025

Free Cash Flow Annual

-2.1M -1.4M -700K 0 700K 1.4M 2.1M 2022: -1.8M 2022

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 6M 12M 18M 2024: 11.4M 2025: 15.2M 2024 2025

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.15 -0.10 -0.05 0.00 0.05 0.10 0.15 Q3 '24: -0.12 Q4 '24: -0.13 Q1 '25: -0.11 Q2 '25: -0.11 Q3 '25: -0.10 Q4 '25: -0.11 Q1 '26: -0.11 Q2 '26: -0.11 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.